Teva Loses Exclusivity For Generic Risperdal; Mylan To Launch Its Product
Executive Summary
Mylan is set to become the second generic manufacturer to launch a generic version of the antipsychotic drug Risperdal (risperidone), cutting short Teva's marketing exclusivity
You may also be interested in...
Teva May Have To Forfeit Exclusivity For Hyzaar/Cozaar Generics
FDA's recent wave of decisions outlining when generic firms forfeit their 180-day exclusivity appears destined to wipe out one of Teva's most prized possessions: exclusivity for Merck's Hyzaar and Cozaar
Teva May Have To Forfeit Exclusivity For Hyzaar/Cozaar Generics
FDA's recent wave of decisions outlining when generic firms forfeit their 180-day exclusivity appears destined to wipe out one of Teva's most prized possessions: exclusivity for Merck's Hyzaar and Cozaar
Generic Firms’ Ability To Seek Declaratory Judgment Limited By Federal Circuit
The Federal Circuit U.S. Court of Appeals has provided further guidance as to when generic companies can seek a declaratory judgment that they do not infringe a patent